© 2021 MJH Life Sciences and Center for Biosimilars®. All rights reserved.
© 2021 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
January 9, 2021
Pharmacokinetic (PK) parameters matched up with those of reference trastuzumab in an extended analysis of data from the HERITAGE trial.
January 4, 2021
Among patients treated for metastatic breast cancer, 40% switched to ABP 980.
December 15, 2020
In little over 1 year of use in patients with breast cancer, trastuzumab biosimilars have seen rapid growth in uptake.
December 10, 2020
Two studies of trastuzumab biosimilars have improved understanding of these medicines as monotherapy and in combination with other agents in metastatic breast cancer.
December 9, 2020
Investigators explained the potential for durable antitumor efficacy in patients with human epidermal growth factor receptor 2 (HER2)-expressing or -driven tumors who have exhausted other treatment options.
November 24, 2020
GP2 peptide/G-CSF in HER2-equivocal and -positive breast cancer has shown promise.